• Je něco špatně v tomto záznamu ?

Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum

A. Jabor, T. Vacková, Z. Kubíček, J. Komrsková, M. Protuš, J. Franeková

. 2021 ; 521 (-) : 59-63. [pub] 20210618

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21024903

BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL receptors. Inhibition of PCSK9 increase uptake of LDL-particles and pathogen-associated molecular patterns (PAMPs). The aim of our study was to evaluate biological variation of serum PCSK9. METHODS: Within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a 6-week protocol (7 samples, equidistant time intervals). Serum concentration of PCSK9 was measured by a Quantikine ELISA assay (R&D systems, Bio-Techne Ltd., UK) on a DS2 ELISA reader (Dynex Technologies GmbH, Germany). Precision (CVA) was assessed by duplicate measurements. Two methods with different levels of robustness were used for the estimation of CVI, SD-ANOVA and CV-ANOVA method. We calculated the index of individuality and reference change values. The experiment was fully compliant with EFLM database checklist. RESULTS: The within-subject values of PCSK9 in healthy persons, as calculated by two statistical methods, were 23.2% (SD-ANOVA with CVA of 5.6%) and 26.6% (CV-ANOVA with CVA of 4.8%). The CVG was 10.9% (SD-ANOVA), index of individuality and RCV were 2.13 and 66.3%, respectively. CONCLUSIONS: The high index of individuality indicates that common reference intervals can be used to interpret serum PSCK9 values.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21024903
003      
CZ-PrNML
005      
20211026134306.0
007      
ta
008      
211013s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.cca.2021.06.023 $2 doi
035    __
$a (PubMed)34153278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Jabor, Antonín $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic
245    10
$a Biological variation of proprotein convertase subtilisin/kexin type 9 (PCSK9) in human serum / $c A. Jabor, T. Vacková, Z. Kubíček, J. Komrsková, M. Protuš, J. Franeková
520    9_
$a BACKGROUND: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is involved in the regulation of LDL receptors. Inhibition of PCSK9 increase uptake of LDL-particles and pathogen-associated molecular patterns (PAMPs). The aim of our study was to evaluate biological variation of serum PCSK9. METHODS: Within-subject (CVI) and between-subject (CVG) biological variations were assessed in 14 healthy volunteers in a 6-week protocol (7 samples, equidistant time intervals). Serum concentration of PCSK9 was measured by a Quantikine ELISA assay (R&D systems, Bio-Techne Ltd., UK) on a DS2 ELISA reader (Dynex Technologies GmbH, Germany). Precision (CVA) was assessed by duplicate measurements. Two methods with different levels of robustness were used for the estimation of CVI, SD-ANOVA and CV-ANOVA method. We calculated the index of individuality and reference change values. The experiment was fully compliant with EFLM database checklist. RESULTS: The within-subject values of PCSK9 in healthy persons, as calculated by two statistical methods, were 23.2% (SD-ANOVA with CVA of 5.6%) and 26.6% (CV-ANOVA with CVA of 4.8%). The CVG was 10.9% (SD-ANOVA), index of individuality and RCV were 2.13 and 66.3%, respectively. CONCLUSIONS: The high index of individuality indicates that common reference intervals can be used to interpret serum PSCK9 values.
650    _2
$a LDL-cholesterol $7 D008078
650    _2
$a lidé $7 D006801
650    12
$a proproteinkonvertasa subtilisin/kexin typu 9 $7 D000071449
650    12
$a LDL-receptory $7 D011973
650    _2
$a subtilisiny $7 D013381
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vacková, Tereza $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic
700    1_
$a Kubíček, Zdenek $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic
700    1_
$a Komrsková, Jitka $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic
700    1_
$a Protuš, Marek $u Department of Anesthesiology, Resuscitation, and Intensive Care, Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660/32, 121 08 Praha 2, Czech Republic
700    1_
$a Franeková, Janka $u Institute for Clinical and Experimental Medicine, Department of Laboratory Methods, Vídeňská 1958/9, 140 21 Praha 4, Czech Republic; Third Faculty of Medicine, Charles University, Ruská 87, 100 00 Praha 10, Czech Republic. Electronic address: jafa@ikem.cz
773    0_
$w MED00009464 $t Clinica chimica acta; international journal of clinical chemistry $x 1873-3492 $g Roč. 521, č. - (2021), s. 59-63
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34153278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026134312 $b ABA008
999    __
$a ok $b bmc $g 1714103 $s 1145410
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 521 $c - $d 59-63 $e 20210618 $i 1873-3492 $m Clinica chimica acta $n Clin Chim Acta $x MED00009464
LZP    __
$a Pubmed-20211013

Najít záznam

Citační ukazatele

Možnosti archivace